Company: ARWR
Filing Date: 2025-09-02
Form Type: 8-K
Source: 0000879407-25-000004
Chunk: 0

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-09-02
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01

Entry into a Material Definitive Agreement

Exclusive licensing and collaboration agreement

On September 2, 2025, Arrowhead Pharmaceuticals, Inc. (the “ Company”) entered into an Exclusive License and Collaboration Agreement (the “ Agreement”) with Novartis Pharma AG, a company organized under the laws of Switzerland (“ Novartis”).

Under the Agreement, Novartis will receive an exclusive license for ARO-SNCA, a preclinical stage investigational RNA interference (“ RNAi”) therapeutic being developed by the Company as a potential treatment of Parkinson’s Disease, and other synucleinopathies, and for other additional collaboration targets utilizing the Company’s proprietary Targeted RNAi Molecule platform.

The Company will conduct and complete all activities through the preclinical stages of ARO-SNCA, and Novartis will be wholly responsible for clinical development, manufacturing, and commercialization activities. The Company will receive $200 million as an upfront payment and is eligible to receive up to $2 billion in potential development, regulatory and sales milestones, and is further eligible to receive tiered royalties up to the low double digits on net product sales.

The transactions contemplated under the Agreement are subject to customary closing conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

The description of the Agreement contained herein does not purport to be complete and is qualified in its entirety by reference to the complete text of the Agreement which will be filed as an exhibit to the Company’s Annual Report on Form 10-K for the year ending September 30, 2025.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

  Exhibit No.      Description                                                                                           
         99.1      Press Release, dated September 2, 2025.                                                               
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
          104      Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).  

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: September 2, 2025

  ARROWHEAD PHARMACEUTICALS, INC.                               
  By:                                  /s/ Daniel Apel          
                                       Daniel Apel              
                                       Chief Financial Officer